Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

A Novel Immunotherapy for Solid Tumors

An immune drug and tumor technology, applied in antitumor drugs, drug combinations, drug delivery, etc., can solve the problems of no breakthrough in chemotherapy, endanger the health of the general public, and poor tumor prognosis, and avoid drug resistance. , prolong life, shrink tumor effect

Active Publication Date: 2022-07-15
王磊 +1
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] At present, the incidence of cancer is high, which seriously endangers the health of the general public. It is usually characterized by a high recurrence rate and causes a huge economic burden on the society.
At present, surgery is still the main treatment for tumors, but radiotherapy and chemotherapy have not made breakthroughs in the treatment of tumors, and the prognosis of stage III and stage IV tumors is still not optimistic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A Novel Immunotherapy for Solid Tumors
  • A Novel Immunotherapy for Solid Tumors
  • A Novel Immunotherapy for Solid Tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] This embodiment provides an immune medicine for treating solid tumors and a preparation method thereof.

[0057] 1. The immunological drugs are type B drugs, including:

[0058] The viral expression vector pLVX-IRES-ZsGreen1 (donated by Beijing Li Keli Laboratory) that simultaneously expresses the Fut1 gene and the B blood group gene, the viral expression vector contains the nucleotide sequence SEQ ID NO. 4, which includes the Fut1 gene, B blood group gene and linker sequence T2A;

[0059] The viral expression vector can express the amino acid sequence shown in SEQ ID NO.2;

[0060] 2. The preparation method of the immune medicine is as follows:

[0061] (1) synthetic nucleotide sequence SEQ ID NO.4;

[0062] (2) If figure 1 As shown, insert SEQ ID NO.4 into the pLVX-IRES-ZsGreen1 vector, and then package the therapeutic virus in 293T cells to obtain the novel immune drug;

Embodiment 2

[0064] This embodiment provides an immune medicine for treating solid tumors and a preparation method thereof.

[0065] 1. The immune drugs are type A drugs, including:

[0066] A viral expression vector that simultaneously expresses Fut1 gene and A blood group gene, the viral expression vector contains the nucleotide sequence SEQ ID NO. The amino acid sequence shown in ID NO.1;

[0067] 2. The preparation method of the immune medicine is as follows:

[0068] (1) synthetic nucleotide sequence SEQ ID NO.3;

[0069] (2) Inserting SEQ ID NO. 3 into the pLVX-IRES-ZsGreen1 vector, and then packaging the therapeutic virus in 293T cells to obtain the immune drug.

Embodiment 3

[0071] In this example, the type A drug provided in Example 2 was used to treat tumors in mice, and the therapeutic effect was observed. The specific operation steps are as follows:

[0072] The MC38 cells used in this example are from the Cell Resource Center, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences; cultured at 37°C, 5% CO 2 The medium was RPMI-1640 medium (Thermo Fisher, USA) supplemented with 10% fetal bovine serum in a humidified atmosphere.

[0073] (1) Three weeks in advance, use A blood group antigen to immunize 6 C57 mice (purchased from Beijing Hua Fukang Company), about 20 g, five weeks old, and immunized once a week after the first immunization; under SPF conditions , mice were housed in cages, each cage housed up to five mice at the Experimental Animal Center of Southern Medical University.

[0074] (2) Inoculation of MC38 colorectal cancer cell line (2×10 5 / only) in the subcutaneous part of the mouse;

[0075] (3) Five days ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a novel immune medicine for treating solid tumors. The immune medicine comprises: a viral expression vector expressing both Fut1 gene and ABO blood group gene, wherein the ABO blood group gene comprises N-acetylgalactosamine transferase gene and / or Galactosyltransferase gene. The immune drug clones the human ABO blood group gene into a medical drug-grade lentiviral vector, and co-expresses it with the Fut1 gene. The target gene sequence is persistently translated in the cell, so that the blood group antigen is expressed in large quantities on the surface of the tumor cell membrane, and it has the ability to be recognized by the corresponding blood group antibody in the serum, thereby causing the activation of complement to kill the tumor cells and reduce the tumor. the goal of.

Description

technical field [0001] The invention belongs to the field of immunotherapy, and in particular relates to an immune medicine, in particular to a novel immune medicine for treating solid tumors. Background technique [0002] The ABO blood group antigen is a glycoprotein and glycolipid on the surface of the red blood cell membrane catalyzed and synthesized by the specific glycosyltransferase encoded by the ABO blood group antigen gene. It is composed of 3 alleles to form 4 main blood types, namely A type, B type, AB type and O type. Blood group antigens exist in three forms: free oligosaccharide type, protein-bound type and lipid-bound type. The first two types can be secreted into various body fluids, and most blood group antigens bound to cell membranes are lipid-bound types. Lipid-binding blood group antigens with immunological activity are located on the outer membrane of the cell membrane, and can be expressed not only by red blood cells, but also widely expressed in othe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/00A61K39/00A61P35/00
CPCA61K9/0019A61K39/0005A61P35/00A61K2039/5256A61K2039/53
Inventor 王磊罗琼
Owner 王磊
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com